PRC200-SS

PRC200-SS
Identifiers
	IUPAC name (1S,2S)-3-(Methylamino)-2-naphthalen-2-yl-1-phenylpropan-1-ol;
CAS Number	492434-58-9 ;
PubChem CID	20631904;
ChemSpider	19318181 ;
ECHA InfoCard	100.207.294
Chemical and physical data
Formula	C20H21NO
Molar mass	291.394 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O[C@H](c1ccccc1)[C@H](CNC)c2cc3ccccc3cc2;
	InChI InChI=1S/C20H21NO/c1-21-14-19(20(22)16-8-3-2-4-9-16)18-12-11-15-7-5-6-10-17(15)13-18/h2-13,19-22H,14H2,1H3/t19-,20-/m1/s1 ; Key:RSZGIFQDUIROGN-WOJBJXKFSA-N ;
(what is this?) (verify)

PRC200-SS is an experimental drug of the triple reuptake inhibitor class that was investigated by the Mayo Clinic.[1][2]

Preclinical toxicology studies of PRC200-SS in cynomolgus monkeys showed dose proportional kidney toxicity,[3] precluding any further drug development.

References

Liang, Y.; Shaw, A. M.; Boules, M.; Briody, S.; Robinson, J.; Oliveros, A.; Blazar, E.; Williams, K.; Zhang, Y.; Carlier, P. R.; Richelson, E. (2008). "Antidepressant-Like Pharmacological Profile of a Novel Triple Reuptake Inhibitor, (1S,2S)-3-(Methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS)". Journal of Pharmacology and Experimental Therapeutics. 327 (2): 573–583. doi:10.1124/jpet.108.143610.
"Triple Reuptake Inhibitors for the Treatment of Depression". Mayo Clinic Ventures.
Guha, Mausumee; Heier, Annabelle; Price, Sally; Bielenstein, Margareta; Caccese, Robert G.; Heathcote, Daniel I.; Simpson, Thomas R.; Stong, David B.; Bodes, Elmarie (2011). "Assessment of Biomarkers of Drug-Induced Kidney Injury in Cynomolgus Monkeys Treated with a Triple Reuptake Inhibitor". Toxicological Sciences. 120 (2): 269–283. doi:10.1093/toxsci/kfr013.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.